Aethlon Medical (NASDAQ:AEMD) focuses on developing unique treatments for life-threatening diseases that lack effective therapies. Specializing in the development of medical devices, Aethlon Medical is best known for its pioneering work on the Hemopurifier®, a device designed to reduce the presence of infectious viruses and cancer-promoting exosomes in the blood. The goal of the company is to address critical unmet needs in global health, including severe viral diseases and cancer, by advancing these novel therapeutic products through clinical trials and eventually to the market, potentially benefiting patients worldwide who currently have limited options. Aethlon Medical is dedicated to innovation in the field of biofiltration and continues to explore the potential applications of its technologies in various medical conditions.